Show simple item record

dc.contributor.authorUngaro, Ryan C
dc.contributor.authorGriffith, Jenny
dc.contributor.authorGarcia-Horton, Viviana
dc.contributor.authorWang, Aolin
dc.contributor.authorCross, Raymond K
dc.date.accessioned2022-09-07T13:29:32Z
dc.date.available2022-09-07T13:29:32Z
dc.date.issued2022-08-04
dc.identifier.urihttp://hdl.handle.net/10713/19680
dc.description.abstractBackground: We compared real-world healthcare resource utilization (HRU), Crohn's disease (CD)-related complications, and time to systemic corticosteroid discontinuation between patients with CD treated with adalimumab versus vedolizumab as initial biologic. Methods: Biologic-naïve adults with CD and ≥2 claims between 05/20/2014 and 09/30/2019 for adalimumab or vedolizumab were identified in the IBM MarketScan research database. Patient characteristics were assessed during the 6-month baseline period before biologic initiation (index date). Adalimumab- and vedolizumab-treated patients were propensity score-matched 1:1 on demographics, disease characteristics, and comorbidities with ≥10% prevalence that differed significantly between groups. Categorical, continuous, and time-to-event outcomes between groups during the 12-month follow-up on/after index were compared with chi-square tests, Wilcoxon rank-sum tests, and Kaplan-Meier analyses, respectively. Results: Adalimumab- and vedolizumab-treated patients were matched (n = 461 per group) and baseline characteristics balanced. Significantly fewer adalimumab- versus vedolizumab-treated patients had a CD-related emergency room visit (12-month proportion: 14.5% vs 21.0%; log-rank P < 0.01) or inpatient admission (14.9% vs 20.2%; log-rank P < 0.05). Rates of CD-related surgeries were similar (9.3% vs 11.5%; log-rank P = 0.282). Among patients without internal/perianal abscess or fistula or intestinal stricture at baseline (N ADA = 360, N VDZ = 364), numerically but not significantly fewer adalimumab- versus vedolizumab-treated patients had CD-related complications at 12 months (18.3% vs 22.3%; P = 0.171). Among patients with corticosteroid use at index (N ADA = 143, N VDZ = 139), significantly more adalimumab- versus vedolizumab-treated patients discontinued corticosteroids (12-month proportion: 90.2% vs 76.3%; log-rank P < 0.001). Conclusions: Patients with CD treated with adalimumab as their first biologic experienced significantly lower CD-related HRU and were more likely to discontinue corticosteroids compared to vedolizumab-treated patients.en_US
dc.description.urihttps://doi.org/10.1093/crocol/otac029en_US
dc.language.isoenen_US
dc.publisherCrohn's & Colitis Foundationen_US
dc.relation.ispartofCrohn's & Colitis 360en_US
dc.rights© The Author(s) 2022. Published by Oxford University Press on behalf of Crohn's & Colitis Foundation.en_US
dc.subjectCrohn’s diseaseen_US
dc.subjectadalimumaben_US
dc.subjecthealthcare resource useen_US
dc.subjectvedolizumaben_US
dc.titleAdalimumab Is Associated With Lower Healthcare Resource and Steroid Use Versus Vedolizumab in Biologic-Naive Crohn's Disease: A Retrospective Claims Database Analysis.en_US
dc.typeArticleen_US
dc.identifier.doi10.1093/crocol/otac029
dc.identifier.pmid36061451
dc.source.journaltitleCrohn's & colitis 360
dc.source.volume4
dc.source.issue3
dc.source.beginpageotac029
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record